Bertrand Pourroy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3538959/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Letters, 2002, 532, 256-260.	2.8	116
2	Antiangiogenic Concentrations of Vinflunine Increase the Interphase Microtubule Dynamics and Decrease the Motility of Endothelial Cells. Cancer Research, 2006, 66, 3256-3263.	0.9	81
3	A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. Scientific Reports, 2017, 7, 2714.	3.3	46
4	High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anti-Cancer Drugs, 2008, 19, 267-273.	1.4	45
5	Therapeutic Drug Monitoring for Dose Individualization of Cisplatin in Testicular Cancer Patients Based Upon Total Platinum Measurement in Plasma. Therapeutic Drug Monitoring, 2006, 28, 532-539.	2.0	31
6	Vinflunine, a Novel Microtubule Inhibitor, Suppresses Calmodulin Interaction with the Microtubule-Associated Protein STOP. Biochemistry, 2007, 46, 14899-14906.	2.5	31
7	Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?. International Journal of Clinical Pharmacy, 2014, 36, 420-429.	2.1	30
8	Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). Cancer Treatment Reviews, 2020, 88, 102063.	7.7	30
9	SFPO and ESOP recommendations for the practical stability of anticancer drugs: An update. Annales Pharmaceutiques Francaises, 2013, 71, 376-389.	1.0	25
10	Dose Individualization of Carboplatin After a 120-hour Infusion Schedule: Higher Dose Intensity but Fewer Toxicities. Therapeutic Drug Monitoring, 2006, 28, 212-218.	2.0	23
11	Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine. Anti-Cancer Drugs, 2006, 17, 181-187.	1.4	21
12	CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics, 2012, 13, 393-397.	1.3	17
13	Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma. Anti-Cancer Drugs, 2006, 17, 1231-1234.	1.4	11
14	Development of a rapid risk evaluation tool for herbs/drugs interactions in cancer patients: a multicentric experience in south of France. European Journal of Cancer Care, 2017, 26, e12752.	1.5	10
15	Providing Oncology Pharmacy Services During the Coronavirus Pandemic: French Society for Oncology Pharmacy (Société Francaise de Pharmacie Oncologique [SFPO]) Guidelines. JCO Oncology Practice, 2020, 16, e1282-e1290.	2.9	6
16	Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2014, 71, 1288-1291.	1.0	3
17	Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. International Journal of Pharmaceutics, 2015, 495, 956-962.	5.2	3
18	Keeping sterile water for injection cold enough for reconstitution of azacitidine in isolators. American Journal of Health-System Pharmacy, 2014, 71, 180-181.	1.0	2

#	Article	IF	CITATIONS
19	Availability of Morphine Oral Solution for Childhood Cancer Patients in Low-Income Countries: Compounding and Stability Study in a Cote d'Ivoire University Teaching Hospital. Journal of Pain and Symptom Management, 2020, 59, e10-e13.	1.2	2
20	Keeping sterile 0.9% sodium chloride, 5% dextrose, and lactated Ringer's solutions for injection cold enough for dilution of decitabine in isolators. American Journal of Health-System Pharmacy, 2016, 73, 748-749.	1.0	0
21	Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration. American Journal of Health-System Pharmacy, 2017, 74, 1217-1218.	1.0	Ο
22	Safety of chemotherapy prescription and production software: proposal of specific guidelines to test new versions. European Journal of Hospital Pharmacy, 2017, 24, 193-193.	1.1	0